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Abstract 
Proteinase-activated receptor 2 (PAR2) may link inflammation with the 
progression of cardiovascular diseases. We examined the potential of mouse mast cell 
protease 7 (mMCP-7), an enzyme similar to human mast cell p tryptase (hMCP-trypta ·e), 
to activate PAR2-dependent vasodilation and the interaction of Ca2+ -activated K+ channel 
(Kca) activation by PAR2 with eNOS-dependent relaxation in the aorta. Aortas from mice 
expressing PAR2 (PAR2 +/+) and PAR2 knockout (PAR2 -/-)mice were used to 
bioassay the PAR2 activity of mMCP-7 and PAR2-activating peptide (2fly) in the 
presence of inhibitors ofKca· mMCP-7 did not produce relaxation responses like hMCP-
tryptase in the mouse aorta and inhibitors of Kca channels did not affect PAR2-mediated 
endothelial nitric oxide synthase dependent-relaxations of the aorta. These data highlight 
species and mechanistic heterogeneity in the ability of an orthologous enzyme agonist to 
activate PAR2 in different arteries. The results emphasize the need for cautious 
interpretations of studies assessing the pathophysiological role ofPAR2 in different 
animal models. 
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Introduction 
Background 
Proteinase-activated receptors (PARs) are members of the G protein-coupled 
heptahelical, tran membrane domain superfamily. There are 4 PARs: PARI. P/\R2. 
PAR3, and PAR4; named in the order of their protein sequence discovery (Hollenberg. 
2003). PARs are expressed on many cells and are abundant throughout the cardiovascular 
and circulatory systems. PARI is expressed on platelets (Vu eta/. , 1991), fibrohla ts 
(Connolly eta/., 1996), endothelial cells, smooth muscle, and the myocardium (Hamilton 
eta/., 2002). PAR2 is expressed on the epithelium and endothelium (D'Andrea et al., 
1998), leukocytes (Dery et al. , 1998), and vascular smooth muscle (Bono et u/ .. 1997). 
PAR3 is expressed on medium sized arteries (0' Andrea et al. , 1998; Molino et al., 1998), 
human bone marrow megakaryocytes (Ishihara eta/. , 1997), and platelets (Kahn eta! .. 
1998). P AR4 is expressed on platelets (lshihara eta!., 1997), megakaryocytes (Kahn el 
a/., 1998) and cardiomyocytes (Sabri eta!., 2003). Their broad expression has led to 
reports of many putative biological functions. 
PARs are activated differently than other G-protein coupled receptors. All PARs 
are acti vated by serine proteases which cleave theN-terminus of the receptor at specitic 
locations. This exposes speci fie peptide residues unique to each PAR which act a ' 
tethered ligands by interacting with their second extracellular loops, producing activated 
conformations. As noted in Table 1. there is no overlap between the capacity of hMCP-
tryptase to activate PAR2 with PAR I, PARJ , and PAR4. Enzymatic cleavage of PAR2 
by all enzyme activators exposes the amino-terminus peptide sequence LIGRL, 
,-------------------------------------------------------------------
Table 1. List of enzymes that recognise PARt, PAR2, PAR3 and/or PAR4 as being 
substrates. Enzymes listed are seri ne proteinases that have been identitiecl as being able 
to either activate or di sarm the receptors. References are provided in the text. 
PARI PAR2 PAR3 PAR4 
r---------------,_---------------r----------------+----------------
Thrombin 
Factor Xa 
Granzyme A 
Gingipain 
Trypsin 
Human mast cell P-
tryptase 
Factor VIla 
Factor Xa 
Proteinase-3 
Thrombin Thrombin 
Trypsin 
Cathepsin G 
Gingipain 
in rodents, and SLIGVK in humans (Hollenberg, 2003). This conserved feature of PARs 
across species has enabled development of pharmacological tool s such as PAR-activat ing 
peptides (PAR-AP) that have then been used to study the biological effects or activating 
PARs in many different animal models. 
PAR2-activating peptides 
Synthetic peptides (5-14 amino acid residues) with sequences corre ponding to 
the revealed tethered ligand activate the PARs with the same action and ubsequent 
signaling as serine proteinases (Schmidlin eta!., 200 I) . These peptide agonists of PARs 
2 
and everal amino-terminal modified pcptidic compounds arc referred to as PAR-
activating peptides (PAR-APs). Table 2 provides a list of PAR-AP a ·sociated with 
different PARs from several species. As shown in Table 2. the PAR2-AP 2tly is specitic 
for PAR2 and is amongst the most potent agonist for PAR2 described having 10- 300 
times more potency than SLIGRL-NH2 (McGuire eta/., 2004). 2fly was derived from 2-
furoyl-LIGKV-OH which mimicked the actions ofSLIGRL-NH2 in vivo in a mouse 
model of chronic arthritis (Ferrell eta/., 2003). 2-furoyi-LIGKV -OH exhibited more 
prolonged activity in comparison to SLIGRL-NH2 . TheN-terminal substitution of the 
serine in SLIGRL by a furoyl group may protect PAR2-AP from endogenous 
aminopeptidases resulting in greater bioavailability and prolonged activity. The addition 
of ornithine to the carboxy terminal (intended to facilitate radiolabeling) increased 
potency (Vergnolle et al. , 1998; Maryanoff eta! .. 2001). Activating PARs with PAR-APs 
in animal models of diseases has provided some insight into possible cardiovascular 
functions of PARs in vitro and in vivo. An understanding of the mechanisms of actions of 
PAR-AP in vitro may help in determining how PARs could be used as therapeutic agent 
targeting the vasculature. 
3 
--
Table 2. Synthetic peptides for activating PARt, PAR2, PAR3, and PAR4 
PARI PAR2 PAR3 PAR4 
FLLRN-NH2 (humans, SFLLRN-NH2 None GYPGQV-N~b 
rat, mouse) (human, rat, mouse) (human) 
TFLLR-NH2 SLIGKV-NH2 (human) GYPGKF-NH2 
(mouse. rat) 
TFRIFD SLIGRL-NH2 (mouse, 
rat) AYPGKF-NH2 
trans-cinnamoyl-
(human) 
LIGRLO- NI-h 
2-furoyl-LIGRLO-
amide (2fly) 
P R2 has numerous putative roles within the vasculature including regulation of 
blood pressure and vascular tone through endothelium-dependent smooth mu cle 
re laxation (Cock el a/., 2000; Damiano el a/., 1999; Hwa el ul. , 1996; aifeddine eta/ .. 
1996; AI-Ani eta/., 1995), alteration ofva cular permeability (Vergnolle et ul. , 1999). 
protection again t coronary i chemia reperfusion injury (Napoli eta/., 2000) and the 
induction of vascular smooth muscle proliferation (in cultured cells; eg. s e Bono et a!., 
1997). A specific endogenous activator of PAR2 that would be in po ition to 
physiologically activate PAR2 in the vasculature has not yet been identified, therefore the 
exact function of activating PAR2 remains unclear. However, the pharmacological 
actions of PAR2- P on ascular smooth mu cle would suggest that PAR2 acti ation may 
play an important role in modulating hemodynamics i.e. acutely lowering blood pressure 
as a result of peripheral vasodilation. Indeed PAR2 knockout mice (PAR2 -/-)were found 
to have a modest blood pressure phenotype characterized by significantl y i ncreascd 
systolic pressures (4% higher than controls) and pulse pressures (10% high~r than 
controls) as measured by radiotelemetry (McGuire eta/., 2008). 
PAR2-dependent relaxation of vascular smooth muscle 
There are two mechanisms that have been reported to cause PAR2-dependent 
vasodilation of blood vessels; 1. Nitric oxide production and 2. Endothelium-dependent 
hyperpolarization (EDH) (reviewed in McGuire et al., 2004). Both mechanisms are 
dependent on activation ofPAR2 on endothelial cells that initiates increasing intrace llular 
calci urn, but there has been some heterogeneity reported about the components of the 
subsequent pathways. 
In the first mechanism, PAR2 activation elicits an increase in intracellular calcium 
which results in calcium-calmodulin activation of nitric oxide (NO) synthesis by 
endothelial NO synthase (eNOS) through the oxidation of L-arginine to L-citrulline. NO 
diffuses into the adjacent smooth muscle cell where it binds to the heme active si te of 
soluble guanylyl cyclase which catalyses production of 3.5 cyclic guanosine 
monophosphate (cyclic GMP) from guanosine triphosphate. Cyclic GMP accumulation 
activates cyclic GMP-dependent kinases that phosphorylate numerous proteins, resulting 
in a net effect of increasing intracellular sequestration and extrusion of calcium from the 
vascular smooth muscle cell (McGuire et al., 2004). This mechanism is inhibited by the 
eNOS inhibitor L-NAME and is absent in eNOS knockout mice (McGuire et al., 2002). It 
is the major mechanism promoting PAR2 induced vasodilation in large diamete r arteries. 
5 
The second vasodilator mechanism utilized by PAR2 is independent of 0 
production. PAR2 promotes an increase in intracellular calcium in endothelial cells which 
is associated with the concurrent development of endothelium-dependent 
hyperpolarization in the underlying vascular smooth muscle. The common and best 
supported explanation for the occurrence of hyperpolarization is that calcium released 
from intracellular stores within the endothelium activates small- (SKca) and intennediate-
(IKca) conductance calcium-activated potassium channels. Endothelial hyperpolarization 
is then conducted through myoendothelial gap junctions causing the vascular smooth 
muscle cell hyperpolarization (McGuire et al., 2004). Hyperpolarization of the 
membranes of vascular smooth muscle cells results in decreased entry of calcium through 
L-type calcium channels with a net lowering of intracellular calcium and vascular tone. 
This mechanism is blocked by selective Kca inhibitors in mice (McGuire et a!., 2002; 
McGuire et al., 2004; McGuire et al., 2007). It is also reduced by barium (an inhibitor of 
inward rectifying K+ channels) and ouabain (inhibitor ofNa+/K+ ATPases) likely as a 
result of the depolarizing effects of the later compounds on the vascular smooth muscle 
cells (McGuire eta!., 2002; McGuire et al., 2004). Reports of PAR2 mechanisms of 
action involving Kca have predominantly been observed in small diameter arteries. 
A heterogeneous list of EDH mechanisms have been described for numerous G 
protein coupled receptor agonists including bradykinin and acetylcholine (reviewed in 
McGuire et a!., 200 I). Some researchers have proposed that the activation of receptors 
on endothelial cells (e.g. muscarinic, bradykinin) results in the release of diffusible 
compounds (other than NO and prostacyclin that are synthesised by endothelial enzymes) 
which promote vascular smooth muscle cell relaxation. In all such reports. de nom 
6 
compounds have been isolated after stimulation of endothelial cells with non-PAR2 
ba ed drugs that produce similar endothelium-dependent hyperpolarization or hlood 
vessels (McGuire et al., 2001 ; Yanhoutte el a/ .. 2007). No one has been ab le to isolate a 
hyperpolarizing compound which has been produced by the endothelium after PAR2 
stimulation. Even with the vast heterogeneity of chemical factors that have been isolated 
as co-called EDH factors , extending such findings to PAR2-based signals remains largely 
unsupported by pharmacological inhibitor studies (McGuire et al.. 2002; McGuire et al.. 
2004; McGuire et al., 2007). Nevertheless, without exception Kca have been identified as 
essential components initiating endothelium-dependent hyperpolarization of vascular 
smooth muscle cells by P AR2. 
Calcium-Activated Potassium Channels (Kca) 
Studies involving gene sequencing, pharmacology, and channel conductance 
indicate that there are three broad categories of Kca channels. Large (BKc8), intermediate 
(I Kca), and small (SKca) conductance Kca channels have been identified in the 
vasculature. Activation of these channels may be linked to intracellular calcium levels 
and coupled to, or independent of, changes of membrane potential. The hasic functional 
unit of a Kca channel is the presence of multi a-subunits that form a symmetric K+ 
permeable pore (Jensen et al. , 2002). This complex is also the target of inhibitors. 
BKca channels are expressed in vascular smooth muscle, but are not expressed on 
the endothelium (Trigglc, 2005). BKca channels exhibit relatively higher single-channe l 
conductance of approximately 250 pS compared to SKca (5-I 0 pS) and IKca channels 
(20-40 pS) (Vergara el al .. 1998). BKca are modulated by membrane potential 
7 
depolarization and activated by increases in intracellular calcium concentration (Toro C!l 
a/ .. 1998). As a result of these characteristics. these channels are proposed to play a role 
in providing feedback inhibition of the activity of voltage-dependent calcium channels 
(i.e. to counter vasoconstriction) (Vergara et al., 1998). BKca channel pores are tctramers 
of a-subunits containing numerous negatively charged residues which are highly 
conserved among different species (Vergara el a!., 1998, Kamouchi el a! .. 1999). their 
amino acid sequence is commonly comprised of several different splice variants of the 
Slo gene (Atkinson et al., 1991. Knaus et al., 1995). Four accessory p !-subunit integral 
membrane proteins having two transmembrane loops form the pore. The amino- and 
carboxyl-terminus reside within the cell, and interact with the pore-forming tetramer. 
Basic channel properties such as ion selectivity and voltage-dependence are determined 
by a subunit composition. The interaction of the p 1-subunits modulates these properties. 
Deletion of the p 1-subunit uncouples BKca channels from calcium sparks arising from the 
sarcoplasmic reticulum. This is proposed to increase vascular tone and contribute to 
hypertension (Lohn eta!., 200 I). The co-expression of the p )-subunit results in increased 
calcium sensitivity of the channel and higher intracellular calcium concentrations creating 
a negative shift in the voltage range of activation. (Kamouchi et al., 1999). With the 
exception of being proposed as a vascular smooth muscle receptor for endothelial-derived 
arachidonic acid metabolites such as epoxyeicosatrienoic acids (EETs), BKca activation 
likely does not mediate EDH mechanisms in response to agonists such as PAR2. 
IKca and SKca are expressed on endothelial cells and are absent in vascular 
smooth muscle. These channels are consistently involved with EDH mechanisms 
(McGuire eta/ .. 2001, Vanhoutte, 2006). IKca channels are voltage-independent and have 
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single channel conductance values of30-39 pS (Jensen eta/ .. 1998). The IKca channel 
gene (also referred to as SK4 gene) encodes a 427 amino acid protein with a short N-
terminal component followed by a six transmembrane domain and a long C -terminal tail. 
Both termini are intracellularly located and the K +- channel pore region is located hetween 
transmembrane domains five and six (Jensen eta/., 2001). Intracellular free calcium 
concentration greater than 50-100 nM is sufficient to generate a steady IKca channel 
current and above such threshold these channels are open at all membrane potentials i.e. 
voltage independent (Jensen eta/., 2002). The opening of TKca channels is triggered by 
calcium-bound calmodulin binding to the C-terminal of the channel (Fanger eta!., 1999). 
IKca have been reported to co-localise to sites of intercellular calcium release at the 
endothelium sarcoplasmic reticulum and myoendothelial gap junctions. This localization 
provides an opportunity for the channels to modulate myoendothelial communication. 
SKca are encoded by SK l, SK2 and SK3 genes. The protein N- and C -termini . 
reside within the cytoplasm and are separated by six transmembrane domains. There is a 
re-entrant loop between the 5111 and 6111 transmembrane domains that is believed to 
modulate selectivity and the conduction pathway forK+ in a manner similar to that 
observed in IKca- Molecular, biochemical, and electrophysiological studies have 
demonstrated that calcium gating in SKca channels is promoted by heteromeric assembly 
of a subunits with constitutively associated calmodulin. This serves as the intrinsic 
calcium sensors for the channels as in the case of IKca- Calcium-independent interactions 
of these channels with calmodulin promotes proper subcellular trafficking and final 
expression in the plasma membrane (May lie et al., 2004).The activation of the outward 
K+ hyperpolarizing membrane potential currents resulting from the opening of Kca are 
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dependent on calcium released from the sarcoplasmic reticulum. and augment fwiher 
calcium intlux into the endothelium through non-selective cation channels. This allov .. ·s 
the channels to modulate the activity of other calcium-calmodulin dependent enzymes 
such as endothelial NO synthase. 
Characteristics of Mast Cells 
Mast cells are polymorphonuclear leukocytes. These cells contain enzyme-rich 
lysosomes that can degrade infectious microorganisms and play an important role in 
immunological protection against microbial infections (Payne eta/ .. 2004). Other roles 
attributed to mast cells include wound healing and producing anaphylactic reactions 
(Thomas et al., 1998, Cairns et al .. 2005). In the latter case, anaphylactic responses arise 
from the release of granules containing histamine, heparin, tryptases. and numerous 
cytokines from mast cells (Coico et al., 2003). These substances (released upon 
activation of mast cells by the cross linking of immunoglobulin E antibody receptors or 
the activation of complement proteins) cause a localised increase in blood flow and a 
leakage of fluid (edema) and plasma proteins into the tissue. This causes an inactivation 
of antigenic agents, sometimes at the consequences of disrupting pathological organ 
function (Guyton, 2006). These compounds also activate sensory neurons increasing the 
perception of pain (nociception) that is associated with inflammatory reactions (Barbara 
et al., 2007). Human mast cells are distinguished phenotypically by different anatomical 
locations (mucosal versus connective tissue) and neutral proteases (characterized by their 
e lectrophoresis isoelectric point). Mucosal mast cells contain mostly tryptases. wh ile 
connective tissue mast cells found in the parenchyma of the lungs or within skin layers 
10 
contain trypta e ·. chymases and carboxypeptidases (Cairn . 2005). Numerous ub tances 
released by mast cells have been assessed with respect to their involvement in 
inflammatory respon es within the cardiovascular system. 
Tryptase 
Tryptases are serine proteases released from mast cells that cau e microva cular 
akage and int1ammation during allergic reactions (Yoshinori el a/., 2005). Basophils 
(the only other cell type known to contain tryptases) have significantly lower levels of 
trypta e than ma t cells (Castells el a/., 1987). Tryptases hydrolyze peptide bond on the 
carboxy- terminu of basic residues. The difference between trypta es and tryp in acti ity 
relates to the ideal/preferred sequences that are 3 amino acids upstream and 3 amino acids 
downstream of the hydrolysed bond of potential substrates. The 5 tryptases isolated from 
humans are named a,~. y, 8 and E forms (Cairns, 2005). While sharing a common family 
name, each tryptase form has unique substrate selectivity. The ~-form has little overlap in 
preferred substrates with the other tryptase (which have chyma e activity) and has a 
unique 3 dimensional structure. Since it is the only tryptase known to activate PAR2 it 
will be the focus of further discussion. 
~-trypta e i the most abundant tryptase in mast cells. Its concentration varies 
depending upon th location; 35 pg in mast cells located in connective ti sue and 12 pg in 
mast cells located in mucosal (lung) tissue (Cairns, 2005). Concentrations of P-tryptase 
are increased in systemic anaphylaxis and other hypersensitivity allergic reactions 
(a thma. interstitial lung disease, and rheumatoid arthritis). Ba cline values in asthmatic 
are rep011ed a being 2 ng P-tryptase per ml of Ia age fluid. which are igni ficantly higher 
than v hat is found in non-asthmatic human (Cairns, 2005). ~-tryptase up-regulates I L-1 ~ 
II 
and IL-8 secretion, enhances the presence of intracellular adhesion molecule /selectins on 
endothelial cells. mediates accumulation of neutrophils and eosinophil . produce 
va cular leakage, and is mitogenic for epithelial cells. fibroblasts. and smooth muscle 
cells in culture (Steinhoff eta!., 2005). 
Human mast cell ~-tryptase (hMC~-tryptase) is a tetramer protein that is stabilised 
by negatively charged heparin proteoglycans. Upon dissociation of heparin, the tctramer 
separates into monomers that are not associated with tryptase-specilic catalytic activity 
(Cairns, 2005). The crystal structure of ~-tryptase consists of a flat-ringed fram formed 
by four monomers which surround a narrow central pore. This pore contains four 
catalytic sites, each facing inward from the walls of the frame. The pore size restricts 
entry of large substrates and proteinase inhibitors into the catalytic sites (Pereira eta!., 
1998). Endogenous ~-tryptase inhibitors have been isolated. It is thought that the 
dissociation of ~-tryptase into monomers is the normal rate-limiting event to its activity. 
[n mice. two orthologous isoforms of human ~-tryptase have been .proposed, mMCP-6 
and mMCP-7. Both of these murine enzymes are located on chromosome 17 and each 
features an apparent tetramer composition and similar substrate selectivity as the human 
~-tryptase (Gurish et at., 1993; Gurish et al., 1994). Discovering the substrate targets of 
mMCP-7 and mMCP-6 will provide information about their roles in inflammation. 
PAR2 and human mast cell J3-tryptase relationship 
hMC~-tryptase has been shown to cleave PAR2 receptors on human epithelial and 
endothelial cells in culture (Molino, 1997). PAR2 expressed on rat colonic myocytcs. 
keratinocytes, and guinea-pig myenteric neurons can be activated by ~-tryptase (Compton 
eta! .. 2001 ). hMC~-tryptase has been proposed to link elevated mast cell levels with 
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PAR2 activation during inflammation. hypersensitivit. reactions and wound repair. It is 
thought that PAR2 activation could stimulate the immune response by producing 
endothelial cytokines and adhesion molecules, a response demonstrated to occur in cell 
culture studie ·. If such events are linked then a PAR2 agonist may be therapeutically 
u ed to block inflammatory reactions. 
hMCP-tryptase (both the recombinant and purified from human lung forms) 
degrade neuropeptides such as vasoactive intestinal peptide and calcitonin gene-related 
peptide, which are capable of influencing smooth muscle tone (Cairns, 2005). Fajardo et 
al. (2003) reported that hMCP-tryptase is also a potent gelatinase and such activity may 
contribute to connective tissue degradation associated with diseases such as rheumatoid 
arthritis, independent of PAR2 activation. 
Glycosylation of PAR2 
All four members ofthe PAR family contain N-linked glycosylation sites as do 
most heptahelical G protein-coupled receptors. Human PAR2 encodes 2 sites, I on 
extracellular loop 2 (ECL2) and the other on the receptor N-terminus. The critical role of 
the glycosylation site on ECL2 for PAR2 signalling was demonstrated by Lerner et al. 
( 1996) splicing ECL2 of PAR2 into PAR I and he demonstrated PAR2-specificity for 
ligand recognition within ECL2. Compton et al. (2002) showed that PAR2 N-linked 
glycoslyation regulates both receptor expression and signalJing. Mutations of theN-
terminus equence of human PAR2 and sialic acid-deficient human PAR2 produced 
increased sensitivity in response to P-tryptase activation. It was postulated that 
glycosylation serves to reserve the activation of PAR2 for events associated with 
pathogenic invasion. Under conditions where sialidases are secreted and remove the -
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linked sugars. PAR2 could play a role in mediating responses between the immune and 
vascular system when immune cells recruited to the site of injury release the serine 
proteinases such as P-tryptase. 
PAR2 and inflammation 
A link between PAR2 and inflammation has been supported by many studies. 
PAR2 expression is up-regulated by pro-inflammatory mediators such as tumour necrosis 
factor a, interleukin I P (IL- l p) and lipopolysaccharide in cell cultures (Nystedt el a!., 
1996). PAR2 gene deletion in mice produces a protective phenotype against various 
diseases (arthritis, asthma, colitis) (Schmidlin eta/., 2002; Ferrell et al., 2003; Lindner el 
al. , 2000). Acute activation of PAR2 by injection of PAR2-AP into rat paws, increases 
vascular permeability, granulocyte infiltration, leukocyte adhesion and pain which is 
consistent with the enhancement of inflammation (Cocks et al., 2000; Yergnolle eta/.. 
200 I; Coughlin et al., 2003). PAR2 activation also increases the release of prostanoids 
and cytokines including IL-6 and IL-8 in epithelial and non-epithelial cells (Lourbakos et 
a!., 200 1). PAR2 agonists (PAR2-AP, trypsin, hMCP-tryptase) produce edema, 
granulocyte infiltration and increased intestinal permeability within the colon (Cenac et 
al., 2002). The expression of PAR2 and its activation are implicated with the activation 
of the immune system. 
In contrast to the pro-inflammatory effects of PAR2, this receptor may also play a 
protective role against some diseases. In the respiratory system of mice, the intranasal 
delivery of P/\R2-AP inhibited hyperreactivity and the antigen-induced intiltration of 
eosinophils (De Campo eta!., 2005). Administering PAR2 agonists protected against 
experimental colitis induced by trinitrobenzene sulfonic acid. This protection, mediated 
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by a neurogenic mechanism. was diminished by a calcitonin gene-related peptide receptor 
antagonist (Fiorucci eta/., 200 I). In the gastrointestinal tract PAR2 agonists inhibit th~ 
fonnation of gastric ulcers induced by ethanol and indomethacin (Kawabata et a/., 2002). 
PAR2-AP infusion exerts a protective effect against experimental myocardial i chemia-
reperfusion injury in rats. It enhances myocardial contractile recovery and decreases 
oxidative stress during reflow at the ischemic risk zone (Napoli eta!.. 2000). PAR2-AP 
mediated vasodilation of basi lar arteries in spontaneously hypertensive rats (SHR), 
middle cerebral arteries of pre- and post-stroke stroke prone-SHR and the mesenteric 
arteries of spontaneously hypertensive mice is preserved under conditions where 
endothelial dysfunction to other endothelial receptors exists (Sobey el a/., 1999; Smeda et 
al., 2007; McGuire el a/., 2007). In mesenteric arteries, endothelial dysfunction was 
associated with a reduction in endothelial nitric oxide-mediated vasodilation and the 
persistent PAR2 vasodilation produced K a-mediated vascular smooth muscle 
hyperpolarization (McGuire eta/, 2007). Such findings illustrate that the 
pathophysiological impact ofPAR2 and its activation by serine proteinases varies with 
the surrounding conditions. 
Rationale, Hypothesis, Objectives 
hMCP-tryptase activates human and rodent PAR2. Mouse mast cell prot ase 7 
(mMCP-7) has similar peptide substrate selectivity and structure to hMCP-tryptase. The 
ability of mMCP-7 to activate mouse PAR2 in intact target tissues has never been 
demonstrated. uch information would enhance our understanding of the relationship 
between PAR2 and its endogenous serine proteinase activators in mouse model of 
human diseases. 
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Our tirst hypothe is (hypothe · i I) was that mMCP-7 would activate PAR2 in the 
mouse aorta. Activation of PAR2 causes endothelium-dependent va cular smooth muscle 
relaxation. lfmMCP-7 activated PAR2 it was expected that mMCP-7 would cause 
relaxation of contracted mouse aorta. We tested this hypothesis by determining the effect 
of recombinant mMCP-7 on isometric contracted mouse aorta. Isometric ten ·ion 
recordings of contracted aorta from PAR2-expressing mice (C57B6) and PAR2 knockout 
mice (PAR2 -/-)were used to bioassay PAR2 activation by mMCP-7 in the presence and 
absence of a deglycosylation enzyme (neuraminidase). Control respon es for endothelial 
P R2 activation in response to mMCP-7 were compared to tho e of other PAR2 agonist · 
(trypsin, P-tryptase and 2tly), and the endothelial-dependent vasodilator acetylcholine 
using isometric tension recordings. 
PAR2 activation can cause NO- and KcallKca-dependent va odilation. While the 
endothelium of aorta expresses SKca and IK a. inhibition of eNOS totally blocks PAR2-
AP induced vasodilation. 
Our econd hypothesis (hypothesis 2) wa that the PAR2- P 2ny promotes the 
activation of eNOS causing NO-dependent vasodilation through the activation of SKca or 
IKca· We tested hypothesis 2 by determining the effects of apamin (SKca inhibitor) and 
TRAM-34 (IKca inhibitor) on PAR2-AP, ACh- and SNP-induced relaxation in the mou e 
aorta. The results of these experiments should further our understanding of the 
mechanisms a ociated with PAR2 activation of large conduction art rie in mice. 
16 
Methods and Materials 
Animals 
Male mice 8-16 weeks of age purchased from the Jackson Laboratory (8ar 
Harbor. Maine, USA) were used. In the mMCP-7 studies testing hypothesis I. C5786 
(n= l8) and PAR2 -/- (n=6) mice were sacrificed at 14-18 weeks ofage. In studies 
assessing the etfects of SKca and IKca inhibitors used to test hypothesis 2. C57B6 (n=20) 
mice were sacrificed at 2 1-24 weeks of age. The procedures were approved by the 
Institutional Animal Care Committee of Memorial University and followed the principles 
and guidelines ofthe Canadian Council of Animal Care. 
Materials 
2-furoyi-LIGRLO-amide (2fly) was purchased from Peptides International 
(Louisville, Kentucky USA). TRAM-34 was purchased from Toronto Research 
Chemicals (North York, Ontario). Recombinant mouse mast cell protease 7 (mMCP-7) 
was purchased from R&D systems (Minneapolis, Minnesota, USA). P20 peptide 
e0GPNSKGR/SUGRLDTP45-YGCG) was a gift from Dr. Morley Hollenberg at the 
Universi ty of Calgary (Alberta). Isolated, purified hMCP-tryptase was a gift from Dr. 
Steven Compton at the University of Hull (Hull, UK). All other chemicals used were 
purchased from Sigma Aldrich Canada (Oakvi lle. Ontario). 
Measurements of isometric tension in aorta of mice 
The thoracic aorta (2 mm lengths) was isolated surgically from each mouse killed 
by cervical dislocation. Each artery was cleaned of adherent fat and then placed between 
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a fixed upport micropositioner and force transducer hy 40 )llll diameter tungsten wirt! in 
a 61 OM myograph chamber (Danish Myo Technology, Aarhus. Denmark) filled with 
Krebs solution (pH 7.4, 9 ml) comprised of 114 mM NaCl, 4.7 mM KCI. 0.8 mM 
Kl-hPO.t. 1.2 mM MgCb, 2.5 mM CaCb, II mM D-glucose, 25 mM NaHC03 and 
bubbled with 95% 0 2 I 5% C02. For each artery. the diameter at resting (baseline) 
tension was set to 90% of the diameter that was estimated to produce wall stress 
equivalent to 120 mmHg (Mulvany eta!., 1977). All drug solutions were applied directly 
to the myograph chambers (the dilution factor of stock solutions ranged from 1/ 100 to 
l/1 000), and the i ometric tension changes were recorded continuously thereafter to a PC 
using Danish MyoDaq and ADI instruments Chart software. Flowcharts are provided 
(Appendix A) to outline the experimental design of drug treatment comparisons for 
hypothesis 1 and 2. 
In all experiments, aortic segments from mice were excluded from analyses if 
initial contractions in response to a single test dose of 120 mM KCI did not produce a > 2 
mN increase in force from baseline. Following washout of KCI, U466 19 (a thromboxane 
A2 agonist) concentration-contraction response relationships (CRC) (0.1 nM - 1 ).1M) 
were determined for each segment of aorta. From each CRC a concentration of 
contractile agonist that produced 70-85% of the maximum observed was determined for 
each segment and used to pre-contract arteries when determining relaxation responses to 
compounds (next section). 
In the experiments assessing hypothesis 1. relaxation responses to acetylcholine 
(100 ).1M ACh) ofuntreated (controls) and a 2-3, 6, 8-neuraminidase (40 min)-treated 
C57B6 (controls) and PAR2 -/- mice arteries contracted sub-maximally by U46619 (30 
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nM-100 nM) were recorded to assess the state of endothelium-dependent vasodilator 
capacity. Arteries that did not relax to ACh were excluded fi·om studies. Then. after each 
aortic segment was allowed to re-establish its contracted tension levels, mMCP-7 (I 0 
mU). 2tly (I ~-tM), hMCP-tryptase (I 0 mU, 375 mU, 1770 mU) or bovine pancreas 
trypsin (10 mU, 60 mU, 375 mU) were added in order to test the PAR2 activatable-
relaxation responses. Arteries were then washed with Krebs solution to baseline and once 
again contracted submaximally prior to testing the relaxation response to SN P ( 1 0 ~tM) . 
In a small number of experiments in order to test whether theN-terminus containing the 
tethered I igand sequence of P AR2 could be cleaved by serine proteinases, P20 peptide 
e0GPNSKGR/SLIGRLDTP45- YGCG; 5~-tM) was added after tension recovery (if 
applicable) to exposure to trypsin, hMCP-tryptase or mMCP-7. When P20 is cleaved as a 
substrate by trypsin-like serine proteases (at RJS) the PAR2 activating sequence SLIGRL 
is produced. Thus, P20 peptide can be used to confirm the ability, if any, of serine 
pro teases to recognize the PAR2 activation motif within the N-tenninus. 
In experiments assessing hypothesis 2, ACh, 2fly and SNP concentration-
relaxation response relationships (in randomly assigned orders) were constructed in 
C5786 (controls) mouse arteries contracted submaximally by U46619 (30 nM-1 00 nM). 
After a washout period (30 - 60 min) with Krebs solution, the effects of inhibitors of NO 
synthase (nitro L-arginine methylester; L-NAME I 00 llM), SKca (apamin; I llM) and 
lKca (TRAM-34; I ~-tM, 10 llM) were determined by exposing arteries to the inhibitors 
for 15 minutes prior to the random application of either ACh, 2fly, or SNP. 
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Measurement of the relative serine proteinase activity of purified 
mMCP-7, hMC~-tryptase and bovine trypsin by absorbance 
spectrophotometry 
To compare the relative amount of serine proteinase activity which was added to 
myograph chambers when exposing arteries to mMCP-7, hMCP-tryptase and hovine 
pancreas trypsin, the amidolytic catalysis of a non-selecti ve substrate by each preparation 
of enzyme was assayed. A Beckman DU series 500 single cell module spectrophotometer 
was used with a I 00 J.!l (maximum volume) glass cuvette ( I em light path) filled with 90 
~d of the substrate N-a-benzoyl-D, L-arginine-p-nitroanilide (BAPNA; 1 mM) and I 0 ~tl 
of the test enzyme preparation. The amidolytic activities of mMCP-7 (50 J..t.g/ml), bovi ne 
trypsin ( 1, 5, I 0, 25, 35, 50 J..t.g) and hMCP-tryptase ( 1 nM) were calculated from the rate 
of product (p-nitroanilide) formed, as measured by the change in absorbance at a 
wavelength of 41 0 nm every 15 seconds over a 20 min period. The spectrophotometry 
blank (zero) contained I mM BAPNA solution dissolved in dimethyl sulphoxide solution. 
An extinction coefficient for p-nitroanilide of 8800 L mor1 cm·1 was used for calculation 
of product formation . 1 mU = amount of enzyme that produced a reaction rate of 1 nmol 
p-nitroanilide /min from BAPNA. Enzyme activity is therefore expressed as · Re lative 
BAPNA units (x 1e·\. 
Data Analyses 
Unless otherwise indicated the values reported are mean ± standard error of mean 
(error bars on graphs; sem). Then values represent the number of mice sampled. 
Maximal effect (Enmx) of U466 19 was expressed as a percentage of the contraction by 
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120 mM KCI. Erna~ for each vasodilator wa expressed as percent relaxation: I 00% 
relaxation =-- complete reversal of agonist-induced contracted tone. en ' itivity is 
. 
expressed by pD2 values (negative logarithm of the concentration of agonist which 
produced 50% of its · · rn :L~). Statistical calculations were run u ing Micro ·oft Excel 2003. 
and Graph Pad Prizm version 4. One-way analysis of variance (ANOVA) corrected for 
multiple comparion by Student Neuman Keuls post-hoc test was used to compare 
variables between groups of3 or more treatments. Results were considered significantly 
different at P < 0.05. 
Results 
Contractile Function of C5786 and PAR2 -/-aorta 
Isometric contractions of aortic segments induced by 120 mM KCI as a relative 
measure of viability were not different between C57B6 (6.1 ± 0.3 mN; n = 6) and 
PAR2 -/- (5.5 ± 1.4 mN; n=3). 
Neuraminidase effects on contraction of C5786 and PAR2 -/-aorta 
It was possible that deglycosylation treatment of tissues would be a prerequisite 
for mMCP-7 activation ofPAR2, but this could have caused a confounding effi ct on the 
contractility of the tissues. To determine ifthe deglycosylation treatment like that used by 
Compton et al. (2002), would affect contractile function, aorta from C57B6 and PAR2 -/-
were exposed to neuraminidase prior to contraction with agonists. Contractions by 
phenylephrine and 46619 of neuraminidase-treated aorta of C57B6 and PAR2 -/-mice 
were not different than contractions of untreated (controls) aorta when standardized to 
120 mM KCI (Figure I and 2). 
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CJControl 
• t\euraninidase (45 rrti'm) 
Figure l - Effect of neuraminidase (45 mU/ml) on phenylephrine (n=4) contractions of 
the C57B6 aorta. Values are mean ± ern. 
PAR2 +/+ PAR2 -/-
Figure 2 - Effect of neuraminidase (45 mU/ml) treatment on U46619 (100 nM) - induced 
contraction of the C57B6 (n=6) and PAR2 -/- (n=3) mouse aortas. alues are mean ± ern. 
Effect of neuraminidase treatment on relaxation of phenylephrine and 
U46619 precontracted aorta 
fo bioas ay mMCP-7 activation of mouse PAR2, untreated and neuraminidase-
treated C5786 aortas were contracted by phenylephrine and then the relaxation responses 
to addition of mMCP-7 were recorded. This approach was also repeated in U46619-
treated aorta in order to compare the effects of different contractile agonists on 
relaxations. 2fly- and acetylcholine-induced relaxation responses were used as controls to 
compare the effects ofmMCP-7 to PAR2 and muscarinic endothel ial-dependent 
relaxation. 
mMCP-7 did not cause any relaxation (not different than 0) of either control or 
neuraminidase-treated C5786 aorta that were precontracted by phenylephrine (Figure 3) 
or U46619 (Figure 4). In both phenylephrine- (Figure 3) and U46619- (Figure 4) 
contracted aortas, 2fly and ACh relaxations of C5786 aorta were unaffected by prior 
neuraminidase treatment. 
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Figure 3 - Relaxation responses of phenylephrine-contracted C57B6 aorta by mMCP-7, 2fly, 
and acetylcholine. Aorta were either untreated (controls; n=6) or treated with neuraminidase ( 45 
mU/ml; n=S) prior to contraction submaximally by pheny lephrine (I pM). Values arc mean ± sem. 
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Figure 4 - Relaxation responses of U46619-contacted aorta by mMCP-7 (10 mll/ml), 2fly 
{lf.!M) and acetylcholine (100 11M). Aorta were either untreated (control , n =5) or treated with 
neuraminidase (45 mU/ml, n=7) prior to contraction ubmaximally by U46619 (I 00 nM). Values 
are mean ± em. 
Control and neuraminidase effect on vasodilatory responses in PAR2 
-1- aorta 
To demonstrate the specificity of mMCP-7 and 2fly for the P R2 receptor, 
U466 19 was used to contract the aorta of PAR2 -/- mice and then th re ponses to 
mMCP-7, 2fly, acetylcholine and sodium nitroprus ide were tested in control and 
neuraminidase-treated tissues. Neither mMCP-7 nor 2fly produced relaxation responses 
in control and neuraminidase-treated tissue sampled from PAR2 -/-mice (Figure 5). 
cetylcholine and NP-induced relaxation response did not differ bct"Ween control and 
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neuraminidase-treated tissues nor were these different than those observed in ('5786 
aorta. 
Cl Control 
1 
• Neuraminidase-Treated ( 45 mU/ml) 
mMCP-7 2fly 
Figure 5 - Relaxation responses of PAR2 -/-aorta (n=3) by mMCP-7 (10 mU/ml), 20y (I 
1-!M), acetylcholine (100 I!M) and sodium nitroprusside (100 1-!M). Untreated (controls) and 
neuraminida e-treated (45 mU/ml) PAR2 -/-aorta were contracted by 100 nM U46619 prior to 
determining relaxation re ponses. Values are mean ± sem. 
Relative serine proteinase activity of mMCP-7, bovine pancreas 
trypsin and hMC~-tryptase 
To compare vascular responses to different enzymes it wa necessary to devel p a 
standardization protocol to calculate the equivalent amounts of enzyme to bioa say with 
aorta. Enzyme activities of mMCP-7, hMCP-tryptase and bovine pancreas tryp in were 
measured using a common substrate BAPNA (I mM). Figure 6 illustrates a linear 
relationship between rate of product formation and trypsin concentration using I mM 
BAP A. Figure 7 shows the different amounts of each enzyme that were requin.:d to 
produce the equivalent rates of enzyme activity u ing I mM BAPNA. For reference or 
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our studies to previous repotts, 1 mU of activity was defined by the rate of p-nitroani!ide 
produced by 1 nM bovine pancreas trypsin with I mM BAPNJ\. 
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Figure 6 - Relationship between the rate of p-nitroanilide production and concentration 
of bovine pancreas trypsin in a solution of 1 mM of BAPNA. The dashed line represents the 
linear regression analyses of n=8 experiments. Values are mean ± sem. 
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Figure 7 - Rate of p-nitroanilide production by bovine panct·eas h")'psin (1 0 ~Jglml). 
mMCP-7 (50 ~tg/ml), hMCp-tryptase (0.1 IJglml) using BAPNA (I mM). Each symbol is a 
replicated sample. Values are mean ± sem. 
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Standardized serine proteinase-mediated relaxation responses in 
C5786 aorta 
Using the standardisation protocol mentioned previously to add equivalent 
proteinase activity, PAR2 relaxation activity by mMCP-7, hMC~-tryptase and bovine 
pancreas trypsin were compared. The aortas were contracted sub-maximally as 
determined from U46619 concentration-contraction relationship (Figure 8). 21ly (I ~LM) 
and acetylcholine ( 100 mM) respectively caused 85 ± I% and 80 ± 3% relaxation in 
U46619 ( 100 nM)-contracted C57B6 aorta (n=3 ). 
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Figure 8 - U46619 concentration-contraction relationship in the aorta of C57B6 mice. 
Symbols (n=3) represent the mean ± em. 120 mM KCI contracted aorta (n=7) by 6.3 ± 0.3 m 
from resting tension. 
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Figure 9 - Standardized serine proteinase activity-relaxation response relationships for 
mMCP-7, bovine pancreas trypsin, hMCJl-tryptase and hMCJl-tryptase + neuraminidase in 
U46619-contracted C57B6 aorta. Symbol represent the replicated responses. For clarity 
mMCP-7 (n=3) was nudged-rightward along the x-axis by 4 units. Control (untreated) replicate 
values of hMC~-tryptase overlap at 0% (n=3). 
I 0 mU/ml of trypsin (0%), hMC~-tryptase (0%), and mMCP7 (0%) failed to induct: 
significant relax~tion in the C5786 aortas. The application of60 mU/ml and 375 m U/ml 
of trypsin produced significant relaxation responses 12 ± 6% and 36 ± 6% respectively. 
Alone. hMC~-tryptase (375, 1770 mU/ml) did not induce relaxation response in the 
C57B6 aorta. Prior treatment of the C5786 a011a with neuraminidase was required to a 
induce relaxation response with 1770 mU/ml ofhMC~-tryptase (16 ± 1%) (Figure 9) In 
data not shown, the addition of2fly after exposure to mMCP-7 produced imilar 
relaxation responses to untreated aorta. 
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Responses of C5786 aorta to treatment with serine proteases + P20 
The butTer conditions within the myograph chambers may have reduc..:d the 
activity of the exogenously added serine proteinascs. To furthl:r test this possibi lity the 
aorta were exposed to a peptide corresponding to theN-terminus sequence or PAR2 
(P20) after the addition of the various enzymes (Figure 1 0). P~O peptide added directly to 
pre-contracted C5786 aorta in the absence of enzyme did not elicit any response. While 
different amounts ofmMCP-7, trypsin and hMCP-tryptase were added in combination 
'vVith P20. only P20 peptide added after the recovery of an elicited relaxation by 3 75 
mU/ml bovine pancreas trypsin ( 16 ± 5%) caused another relaxation of C57B6 aorta 
(Figure I 0). 
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Figure 10 - Effects of P20 ± serine proteases on the CS7B6 aorta. Relaxation of the C5 786 
aorta by tryps in, hMCP-tryptase and mMCP7 in the presence and absence of P20 (5 ~M). 
Values are mean ± sem. 
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Effect of Ca2+ -activated K+ channel and NO inhibition on contractility 
of aorta 
U46619 dose response curves were standardized to 120 mM KCI (Figure II: 6.6 
± 0.4 mN; n=20) in C57B6 aorta. Concentration-contractile response relationships of 
inhibitor-treated tissues did not differ from control tissues (E111a, and pD2: control: 246 ± 
10%; 7.7 ± 0.1; n= l5 ; TRAM-34 (1 ~M): 250 ± 15%; 7.8 ± 0.2; n=7; L-NAM E (100 
~tM): 242 ± I 0% ; 8.2 ± 0.1; n=7; TRAM-34 ( I 0 ~M): 226 ± 8 % : 7.6 ± 0.1: n= 13; 
TRAM-34 (10 ~M) and apamin (1 ~M): 227 ± 6%; 7.5 ± 0.1; n= 14). 
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Figure 11 - Effects of L-NAME and Kca inhibitor on U46619-induced contractions of 
mouse aorta. Untreated (controls; n= l5), L-NAME (n=7), TRAM-34 (IKca inhibitor: I ~LM. 
n=7; I 0 ~M. n= 13) or TRAM-34 + apamin (SKca inhibitor; n= 14)-treated aorta were contracted 
by cumulative add ition ofU46619. Values are mean ± sem. 
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PAR2 AP-induced relaxations of C57B6 aorta 
To test the effects of NO synthase and Kca inhibition on PAR2-mediated 
relaxation, C5786 aortas were lett untreated (controls) or treated with inhibitors prior to 
measuring 2fly-induced relaxations of U46619 pre-contracted aot1a. 2tly induced 
relaxation was reduced by 80% in tissues incubated with an inhibitor of NO synthase 
(I 00 ~-tM L-NAME) compared to controls.TRAM-34 in the presence or absence of 
apamin did not alter 2fly mediated relaxation responses (Figure 12). The potency of 2tly 
mediated relaxation between controls and all Kca inhibitor groups did not differ (Emax and 
pD2: control: 82 ± 2%; 7.6 ± 0.1 ; n=15; TRAM-34 (I ~-tM): 74 ± 6%; 7.7 ± 0.2: n=7: 
TRAM-34 (10 ~tM): 83 ± 4%; 8.0 ± 0.1 ; n=13; TRAM-34 (10 ~-tM) + apamin (I p.M): 84 
± 2%; 7. 7 ± 0.1; n= 14 ). L-NAME reduced Emax to 16 ± 4% but did not signi ticantly alter 
pD:! (7.3 ± 0.2 %) when compared to the control group 
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Figure 12 - Effect of Kc. inhibitor on 2fly-induced relaxations of mouse aorta. Untreated 
(controls: n= 15), L-NAME (n=7), TRAM-34 (IKca inhibitor: I JlM. n=7, 10 JlM, n= l 3) or 
TRAM-34 + apamin (SKca inhibitor; n= l4)-treated aorta were contracted by U46619 (I 00 nM)-
prior to obtaining responses to 2tly. Values are mean ± sem. 
ACh-induced relaxations of C57B6 aortas were reduced by - 95% in tissues 
incubated with 100 J..LM L-NAME compared to controls and all other Kca inhibitor groups 
(Figure 13). Potency of ACh did not differ between controls and Kca inhibitor treatments 
(Emux and pD2: control: 76 ± 4%; 8.2 ± 0.1; n= l5; TRAM-34 ( 1 J..LM): 77 ± 2%; 8 .2 ± 0.3; 
n=7; 7.6 ± 0.2; n=7; TRAM-34 (I 0 J..LM): 69± 4%; 8.0 ± 0.2; n= 13; TRAM-34 (I 0 ~LM) 
and apamin ( 1 J..LM) : 72 ± 2%; 8.1 ± 0.2; n= 14). L-NAME reduced Emax (5 ± 2% ) and did 
not alter the p02 values (7.6 ± 0.2) when compared to acetylcholine relaxation in control 
tissues. 
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Figure 13 - Effects of L-NAME and Kca inhibitor on acetylcholine-induced •·elaxations of 
mouse aorta. Untreated (controls; n= 15), L-NAME (n=7), TRAM-34 (I Ken in hibitor; I 11 M 
n=7; I 0 f..LM n= 13) or TRAM-34 + apamin (SKca inhibitor; n= 14)-treated aorta were contracted 
by U4661 9 ( I 00 nM) prior to determining cumulative concentration response relaxation 
responses. Values are mean ± sem. 
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SNP-induced relaxations of C5786 aorta. 
The relaxation responses of aorta to an endothelium-independent nitrovusodilnh.w 
were tested with SNP (Figure 14). Potency and maximum responses did not differ 
between groups (Ema~ and pD2 : Control: 87 ± 2%; 8.9 ± 0.1; n=15: TRAM-34 (I j..1.M): 82 
± 3%; 8. 7 ± 0.2: n=7; L-NAME ( I 00 ~tM): 87 ± 2%; 8.9 ± 0.2; n=7; TRAM-34 (I 0 ~tM): 
83 ± 3%; 8. 7 ± 0.2; n= 13; TRAM-34 (1 0 j..I.M) and apamin ( I j..I.M): 83 ± 21Yo; 8.8 ± 0.2: 
n=14) (Figure 14). 
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Figure 14 - Effect of inhibitor of Kca on SNP-induccd relaxations of mouse aorta. Untreated 
(controls, n= IS), L-NAME- (n=7), TRAM-34- (IKca inhibitor; I ~tM , n=7; I 0 ~tM, n= 13) or 
T RAM-34 + apam in (SKca inhibitor; n= l4)-treated arteries were contracted by U46619 (1 00 
n M) prior to determ ining relaxation responses to cumulative concentrations of SNP. Values are 
mean ± sem. 
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Discussion 
General findings 
The first objective ofthis thesis was to determine ifmMCP-7 activat~s PJ\R2 in 
the mou e aorta. We found that mMCP-7 did not relax mouse aorta even after 
deglycosylation of mouse aorta by neuraminidase. This occurred des pit~.! the contirmation 
that neuraminidase treatment enabled hMC~-tryptase-sensitiw relaxations to occur in the 
mouse aorta. Since PAR2 activation was observed using the positive controls of PAR2-
AP 2fly and PAR2 activating enzyme trypsin, we conclude that mMCP-7 did not activate 
PAR2 in mouse aorta at the amounts tested in this study. We believe the e data indicate 
that the mMCP-7 isoform of mouse mast cell protease does not reproduce the full range 
of actions attributed to hMC~-tryptase. However, the experiments contained several 
limitations. The relative serine proteinase trypsin-like activity of the mMCP-7 that was 
employed in the relaxation assays was low. This warrants cautious interpretation of thes 
data and possible further study using higher amounts of enzyme activity. 
The second objective of this thesis was to determine ifSKca and lKca inhibitors 
inhibit PAR2-mediated NO-dependent relaxation of mouse aorta. The mouse aorta is 
known to utilise NO tor relaxation by PAR2 and it has been established that PAR2 
activation activates Kca channels in smaller resistance arteries like mesenteric and middle 
cerebral arteries (McGuire et al., 2004; McGuire et al., 2007; Smeda and McGuire. 
2007). Because there are no reports indicating the selective expression of Kca distribution 
amongst different endothelial cells. we hypothesised that if PAR2 activated Kca channels 
in aortic endothelium such action could enhance 0 production and thus, the inhibitors 
of these channels should inhibit PAR2 re laxation of mouse aorta. We found that the 
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inhibitors ofSKca and IKca either alone or in combination (using concentration that 
wou ld inhibit PAR2 in small arteries (McGuire eta! .. 2004: McGuire el a! .. 2007) did not 
inhibit PAR2-induced relaxation of mouse aorta. The Kca inhibitor treatment. also did 
not inhibit endothelial-dependent relaxations by AChor endothelium-independent 
relaxations by sodium nitroprusside. Treatment of aortas with the NO synthase inhibitor 
L-NAME blocked relaxations by both 2fly and ACh. Therefore, it appears that despite 
the ability of PAR2 to activate Kca, these channels plays no role in NO-mediated 
relaxations of contracted mouse aorta by PAR2-AP, ACh nor SNP. 
Activation of PAR2 by serine proteinases in C5786 aorta 
Failure of mMCP-7 to produce any relaxation of contracted C57B6 aorta was an 
unexpected result so experiments were undertaken to compare these responses to other 
serine proteinases in the mouse aorta. Compton eta!. (2002) demonstrated that hMC~­
tryptase was capable of activating PAR2 relaxation in rat aorta after deglycoslyation of 
the tissue. While mMCP-7 was unable to elicit PAR2 relaxations, we did find that hMCB-
tryptase was capable of activating mouse PAR2 after neuran1inidase treatment of tissues. 
This finding was consistent with the notion that in human tissues that hMC~-tryptase is 
an endogenous activator of PAR2. 
In C57B6 aorta, ACh and 2fly produced significant relaxation response 111 
controls and neuraminidase-treated tissues so the endothelium and PAR2 receptors were 
functionally intact in our experiments. Relaxations by 2fly and acetylcholine \\.ere not 
igni ficantly different in neuraminidase-treated and control tissues. which also would 
support the notion that neuraminidase treatment did not a lter the efficacy of endothelial 
PAR2 and muscarinic receptor mediated vasodilation. We demonstrated that 2 fly elicited 
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relaxations were dependent on the expression of PAR2 since responses were absent in 
PAR2 -/-aorta. We used bovine pancreas trypsin. a known po itive control for serine 
proteinase activation of PAR2, to demonstrate relaxation respon es in C5786 aorta. 
Trypsin had been chosen for a secondary purpose allowing us to standardise the amount 
of enzyme added to preparations relative to the units oftrypsin activity. In our 
standardisation protocol experiments. BAPNA was used to as the substrate for peptide 
amidoly1ic activity. It seems possible that the differences between trypsin. hMC~-tryptasc 
and mMCP-7 with respect to causing vasodilation could be related to the low level of 
equivalent enzyme activity in respect to mMCP-7. This was due to a limitation in the 
amount of recombinant mMCP-7 which could be purchased and the amount of purified 
hMC~-tryptase provided by collaborators. Further studies with enzyme preparations 
having higher specific activities and more direct assays of PAR2 activation are 
warranted. 
In addition, the enzyme activities within the myograph chambers were less than 
optimal under the conditions of the bioassay. P20 peptide c-'0GPNSKGRISLIGRLDTP45-
YGCG) was incubated with mMCP-7 and mouse aorta to determine whether the ~nzym 
could produce the PAR2 recognition sequence (SLIGRL). A similar approach had been 
used with hMC~-tryptase and rat aorta (Compton el a!., 2002) which employed identical 
bioassay conditions. We found that mMCP-7 did not elicit relaxation in the presence of 
P20 so these experiments were repeated with tissues exposed to trypsin and hM P-
tryptase. In C5786 aorta. equivalent amounts of hMC~-tryptase and trypsin v.erc addl!d 
to the tissue bath to match the activity ofthe mMCP-7 used previously. P20 elicited a 
relaxation from aorta only at the highest amount of trypsin. Surprisingly, P20 plus 
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equivalent (to trypsin) amounts of hMC~-tryptase did not produce any rdaxation 
responses. We speculate that the rates of hydro lysis of soluble P20 and the in situ PAR2 
tethered ligand differed with respect to the rates of activating PAR2. Alternatively PAR2 
activation by hMC~-tryptase in mouse aorta may require a specitic conformation ol'thc 
tethered ligand that binds to PAR2 (like thrombin to PAR I) in order to achieve the 
subsequent activated receptor conformation. Finally. the negative findings could have 
indicated that mMCP-7 while recognising PAR2 as a substrate may have acted to disarm 
PAR2 rather than activate it. This possibility was not ruled-out by the experiments we 
performed. However, aortas did not show any tachyphylaxis to PAR2-AP after mMCP-7 
treatment which would have indicated internalization following receptor disarming. 
SKca and IKca interaction with NO-mediated relaxation in C5786 aorta 
In our study, the inhibition ofNO synthases by L-NAME was sufficient to block 
2fly and ACh-induced relaxations of C5786 aorta, confirming the central role of NO in 
endothelium-dependent relaxation of this a rtery (McGuire el a!.. 2002b; McGuire eta/ .. 
2004). Since apamin and TRAM-34 did not affect either 2fly or ACh-induced relaxations. 
SKca and IKca, likely do not play a role in modulating endothelial NO-dependent 
relaxations. SNP relaxation responses were also unchanged in the presence ofTRAM-34, 
apamin and L-NAM , suggesting that the pathways subsequent to NO generation were 
insensitive to SKca and IKca blockers. One interpretation of the data is that having PAR2 
linked to SKca and IKca channels may be of no functiona l consequence in the 
endothelium of aorta. 
The ine ffectiveness of Kc:a inhibitors in altering endothelial-dependent relaxation 
response in larger conductance sized artery like the aorta ofC5786 mice invites further 
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explanation. In small resistance arteries. PAR2 activation of Kca is considen:d to be 
es entia! to initiate an EDH response mediated by myoendothelial cell gap junctional 
communication between cells. This hyperpolarizat ion results in dilation of the artcric . . 
The inhibitio n o f Kca also results in complete or partial inhibition of relaxat ion of other 
endothelial-dependent vasodilators such as acetylcholine and bradykinin in mouse 
mesenteric arteries and rat middle cerebral arteries (McGuire et al., 2007: Smcda and 
McGuire. 2007: Pannirselvam ct al., 2006). We offer two explanations why an EDH 
respon e is unseen during PAR2-induced relaxation in C57B6 aorta. The first explanation 
is based on the assumption that PAR2 initiates a mechanism of action for vasodilat ion in 
all arterial beds in the same manner. That is, in small resistance arteries PAR2 activates 
NO synthase as well as an EDH response, which is well-supported by data (McGuire et 
a/ .. 2002; McGuire et al., 2004; McGuire et al., 2007). In comparison, in larger 
conductance arteries while PAR2 activates endothelial NO synthase it also initiates the 
endothelial Kca acti vation, but that the conduction of hyperpolarization is blocked by the 
physical composition of the aortic wall. That is, the internal lamina and e lastin within 
internal layers of aortic wall may act as an e lectrical insulating barrier which would block 
any hyperpolarization response produced by PAR2 and similar EDH-initiating 
vasodilating agents except at sporadic gap junctions. Differential myoendothelial gap 
junction communication i.e. as a result of the internal elastic lamina or the specific 
isoforms of gap junction connexins present, may also explain the lack of an EDH 
response in mou e aorta. Such differences have been observed from high resolution 
electron microscopic morphologica l comparisons of rat femoral to rat mesenteric arteries 
(Sandow and Hill. 2000) and mRNA expression patterns in mice (Ccroni ct al.. 2007). An 
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alternative explanation is that receptors have adapted to signalling mechanisms that are 
also associated with the function ofthe di f ferent vascular beds. In smaller arterial beds 
w here diameter changes are more responsible for regulating blood tlow. PAR2 may have 
adapted to utilize a NO driven relaxation as wel l as an EDH response. which tends to be a 
more rapid response. In larger conduction arteries, PAR2 may only need to utilize NO. 
which functions physiologically less to control vascular tone, but to maintain an anti-
thrombotic surface on the endothelium oflarge diameter arteries. If the latter argument 
holds merit then the link ofPAR2 to Kca and the roles played by Kca may also be more 
important to other cellular functions of the endothelium in the aorta, for example, perhap 
the release of cytokines in response to injury, which were not examined by thi s thesis. 
Conclusions 
mMCP-7 did not appear to activate PAR2 as bioassayed in C5786 ao1ia at the 
amounts tested in this study. Given these findings mMCP-7 did not reproduce the actions 
of hMC~-tryptase on PAR2 on the endothelium and vascular smooth muscle of mouse 
aorta. We conclude that cautious interpretation of experiments is advised when 
investigating the roles played by mast cells and PAR2 in mouse models of cardiovascular 
diseases because enzymes target substrates may not be conserved across species. 
Inhibitors of SKca and IKca did not inhibit the NO-dependent relaxation respon es 
of ACh, SNP or 2tly in C57B6 aorta contracted by U46619. We conclude that Kca do not 
play any role in contributing to relaxation by PAR2 and NO release in "healthy" C57B6 
aorta. We speculate that the link of PAR2 to Kca may contribute to endothelial cell 
function/dysfunction (other than by modulating vascular tone) in cardiovascular 
pathophysiology e.g. Ca2 ~ -driven gene expression (Wang el a/ .. 2007). 
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Appendix A 
Table ] - Flow char1 for hypothesis I. 
Chamber 1 Chamber 2 Chamber 3 
,----------
Chamber~ 
Treatment 120 mM KCI 120 mM KCI 120 mM KCI 120 mM KCI I 
Treatment U46619 DRC U-+6619 DRC U46619 DRC U46619 DRC 
2 c 1 o·' 0-I o·6M) (I 0-10-1 0"6M) c 1 o·' 0-l o·(lM) ( 1 o·' 0-l o·(lM) 
Treatment Neuraminidase Neuraminidase 
3 treatment Vehicle treatment Vehicle (40 min) (40 min) 
--
Treatment 
4 ACh (IOO~M) ACh (IOO~M) ACh (lOO~M) ACh ( IOO~M) 
Treatment 
mMCP-7 (lOmU) mMCP-7 (I OmU) 2fly (I ~M) 2fly {IJ1M) 5 
Table 4 - Flow chart for hypothesis 2. 
C hamber Cha mber Chamber Chamber Chamber Chamber Chamber Chamber 
I 2 3 4 5 6 7 8 
Treatment 120 mM 120mM 120 rnM 120mM 120 rnM 120 mM 120 mM 120 rnM 
I KCI KCI KCI KCI KCI KCI KCI KCI 
U46619 U46619 U46619 U46619 U466 19 U46619 U466 19 U46619 
Treament DRC DRC DRC DRC DRC DRC DRC DRC 
2 (lo·lo_lo· (I o-lo_l o· (lo·lo_lo· (lo·IO_Io· (I o·10- l o· ( 10-lo_l o· ( 1 o·ltl- 1 o· ( 1 o·111-l o· 
6M) 6M) uM) 6M) 6M) uM) ''M) "M) 
TRAM-
Treatment L-NAME TRAM- TRAM- 34 
3 (I 00!-!M) 34 (I !lM) 34 (10!-!M), Vehicle Vehicle Vehicle Vehicle (I O!lM) Apamin 
(I !lM) 
--
Treatment Ach DRC Ach DRC Ach DRC Ach DRC Ach DRC Ach DRC Ach DRC A h DR ' 4 
Treatment SNP SNP SNP SNP SNP SNP SNP NP 
5 DRC DRC DRC DRC DRC DRC DRC DRC 
Treatment 2fly DRC 2fly DRC 2fly DRC 2fly DRC 2fly DRC 2fly DRC 2tly DRC 2tl> DRC 6 
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